{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Davies B"],"funding":["National Institute for Health Research (NIHR)"],"pagination":["e061294"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10008337"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(3)"],"pubmed_abstract":["<h4>Introduction</h4>Degenerative cervical myelopathy (DCM) is a common and disabling condition of symptomatic cervical spinal cord compression secondary to degenerative changes in spinal structures leading to a mechanical stress injury of the spinal cord. RECEDE-Myelopathy aims to test the disease-modulating activity of the phosphodiesterase 3/phosphodiesterase 4 inhibitor Ibudilast as an adjuvant to surgical decompression in DCM.<h4>Methods and analysis</h4>RECEDE-Myelopathy is a multicentre, double-blind, randomised, placebo-controlled trial. Participants will be randomised to receive either 60-100 mg Ibudilast or placebo starting within 10 weeks prior to surgery and continuing for 24 weeks after surgery for a maximum of 34 weeks. Adults with DCM, who have a modified Japanese Orthopaedi"],"journal":["BMJ open"],"pubmed_title":["Targeting patient recovery priorities in degenerative cervical myelopathy: design and rationale for the RECEDE-Myelopathy trial-study protocol."],"pmcid":["PMC10008337"],"funding_grant_id":["CS-2015-15-023"],"pubmed_authors":["Choi D","Alvarez-Berdugo D","Sadler I","Starkey M","Hutchinson PJ","Fehlings MG","Nodale M","Mowforth OD","Papadopoulos MC","Yordanov S","Bishop J","Kotter MRN","Whitehead L","Lamb S","Trivedi RA","Kareclas P","Wilkinson IB","Smith L","Kalsi-Ryan S","Carpenter A","Wilby M","Bacon M","Bond S","Chandran S","Davies B"],"additional_accession":[]},"is_claimable":false,"name":"Targeting patient recovery priorities in degenerative cervical myelopathy: design and rationale for the RECEDE-Myelopathy trial-study protocol.","description":"<h4>Introduction</h4>Degenerative cervical myelopathy (DCM) is a common and disabling condition of symptomatic cervical spinal cord compression secondary to degenerative changes in spinal structures leading to a mechanical stress injury of the spinal cord. RECEDE-Myelopathy aims to test the disease-modulating activity of the phosphodiesterase 3/phosphodiesterase 4 inhibitor Ibudilast as an adjuvant to surgical decompression in DCM.<h4>Methods and analysis</h4>RECEDE-Myelopathy is a multicentre, double-blind, randomised, placebo-controlled trial. Participants will be randomised to receive either 60-100 mg Ibudilast or placebo starting within 10 weeks prior to surgery and continuing for 24 weeks after surgery for a maximum of 34 weeks. Adults with DCM, who have a modified Japanese Orthopaedi","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-04-04T11:27:58.672Z","creation":"2025-04-04T11:27:58.672Z"},"accession":"S-EPMC10008337","cross_references":{"pubmed":["36882259"],"doi":["10.1136/bmjopen-2022-061294"]}}